In the past few months, and due to the recently initiated Phase I/IIa Clinical Trial of the bacteriophage cocktail TP-102, which has been entirely developed in the company for the treatment of diabetic foot ulcers infected by Pseudomonas aeruginosa, Acinetobacter baumannii and/or Staphylococcus aureus, Technophage has recently been featured in different Portuguese interviews, broadcasts and magazines pieces. One of the most recent is the interview given by Miguel Garcia, CEO of Technophage to the Portuguese online journal Link to Leaders.

“TechnoPhage aims to eliminate the three bacteria that are at the origin of the “diabetic foot” through a cocktail of viruses. At the moment the clinical trials are already being carried out in Israel and it is expected that within the next eight weeks we will have the first results regarding the safety and tolerability of the product”, commented Miguel Garcia, CEO of the biopharmaceutical company.

Read the complete interview in Portuguese at Link to Leaders.